More Videos
SPECIAL REPORT
MOST SHARED
- Pharma & Social Media
- CNBC TRANSCRIPT: Warren Buffett & Bill Gates - Keeping America Great
- Cities With the Most Home Price Reductions
- Warren Buffett and Bill Gates Share Their 'Optimism' With Eager Columbia Business Students
- Microsoft's Bill Gates Praises Apple's Steve Jobs For 'Saving the Company'
- Disney Profit, Sales Top Street Forecasts; Shares Jump
- Warren Buffett's $100,000 Offer and $500,000 Advice for Columbia Business School Students
- Is Euphoric Market Ignoring Warning Signs?
- China Fourth Quarter Growth Could Hit 10%: Official
- Obama to Outline Strategy to Boost US Exports to Asia
- EXCERPTS and IMAGES: Warren Buffett & Bill Gates - Keeping America Great
- Microsoft's Bill Gates Praises Apple's Steve Jobs For 'Saving the Company'
- Gold Is a Bad Inflation Hedge—Like Oil: Stock Picker
- Intel's Andy Bryant Offers An Explanation
- US 'Actively Working' on Weaker Dollar: Fund Manager
- Options Boil on Biotech Buyout Rumors
- Warren Buffett's $100,000 Offer and $500,000 Advice for Columbia Business School Students
- Activision Blizzard's "Modern Warfare 2" Sales Break Records
- 5-Star Manager's 5 Stocks for Changing Markets
- Obama to Outline Strategy to Boost US Exports to Asia
- Friday May See 'Risk Trade' Stalling; Dollar in Focus
- Job Market Politics to Keep Interest Rates Low
- AIG, Symbol of Crisis, Watches Its Stock Zoom Back
- Disney Profit, Sales Top Street Forecasts; Shares Jump
- Bill Gates Praises Apple's Jobs for 'Saving the Company'
- Cities With the Most Home Price Reductions
- Is Euphoric Market Ignoring Warning Signs?
- Video Game Sales Plunge, but Have They Hit Bottom?
RSS FEED
Pharma's Market
Text Size 
Genentech [DNA
Loading...
()
] shares dropped three percent today or $2.85 to $81.24 after Roche showed some chutzpah and lowered its bid for DNA. Recently, there'd been reports that the Swiss drugmaker, which already has a majority stake in the California biotech, was going to raise the offer to around $94. So, it was surprising and, some might say, shocking when Roche announced this morning that it was willing to pay $86.50 a share instead of the original $89.
Late today, Genentech put out a press release urging shareholders to tell Roche to take a hike. Dr. Charles Sanders, the chairman of the special committee of the DNA Board of Directors that's been set up to deal with Roche, called Roche's move "unilateral and opportunistic...in an attempt to take advantage of current market conditions."
But in a research note to clients, Bill Tanner at Leerink Swann said investors should take the money. "We believe the shares are fundamentally overvalued." Leerink Swann may trade in DNA.
Other analysts and investors believe Genentech's stock could rally this spring when test results are expected on the cancer drug Avastin as an add-on treatment for colon cancer. If the data are good and the drug gets approved for that use, it could substantially increase Avastin sales. Genentech recently announced that the numbers could be available in April. I'm guessing they'll unveil the so-called topline data at that time and save the details to make a huge splash at this year's American Society of Clinical Oncology meeting.
Geoffrey Meacham at JPMorgan says if that Avastin study goes well that Genentech shares could be worth more than a hundred bucks. "We do not expect the majority of shareholders to participate in this tender offer, where most of the core holders have held the stock for several years and are believers in the adjuvant (add-on Avastin colon cancer treatment) opportunity and the long-term value of the company." JPM has done and wants to do more investment banking for DNA and it makes a market in DNA options, which were apparently active today.
And another Geoffrey...Geoffrey Porges at Sanford C. Bernstein writes, "This is clearly another high risk hardball negotiating strategy by Roche. We believe it has a significant risk of failing to impress sufficient Genentech independent shareholders to close the deal." A part of Bernstein owns at least one percent of DNA.
Now, I'm really looking forward to my live interview next Friday morning with the new Roche CEO Severin Schwan.
That'll be "First on CNBC" on "Squawk Box" at around 7:15 a.m. ET.
It's the first time he's talked to CNBC U.S. since he took over last year and launched the bid for DNA.
If you had the chance, what would you ask him?
Send me your questions or comments to
Data is a real-time snapshot *Data is delayed at least 15 minutes